PROVIDER PROFILE · NPI 1962502013

Brenda PanzeraM.D.

Medical OncologyNew York, NYI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

12,922

Unique beneficiaries

—

Total services

32,214

Distinct HCPCS

Medicare payment

$667K

Peer benchmark

Total Medicare services vs. 506 Medical Oncology providers in NY — top quintile (cohort median 458).

PRESCRIBING · PART D · 2024

Total Rx claims

872

Beneficiaries

—

Total drug cost

$2.0M

Distinct drugs

Brand share

40.6%

Top prescribed drugs

Anastrozole234 claims

Darbepoetin Alfa In Polysorbat114 claims

Letrozole72 claims

Apixaban64 claims

Fulvestrant59 claims

QUALITY · MIPS · 2024

Final MIPS score

100.0

Quality

15.8

Cost

75.0

Improvement activities

40.0

Promoting interop.

100.0

Payment adjustment

1.05%

Group

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

No data available for this provider in 2024.

REFERRAL NETWORK

Where Brenda Panzera's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 8 inbound referrers · 0 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
MOUNT SINAI HOSPITAL	56	278
ENZO CLINICAL LABS, INC.	20	90
Laboratory Corporation Of America Holdings Clinical Laboratory · Raritan, NJ	18	45
Joseph Maklansky Diagnostic Radiology · New York, NY	17	60
LENOX HILL HOSPITAL	16	56
GOLDFARB, ALISAN	14	26
Alain Hyman Diagnostic Radiology · New York, NY	13	53
Marc Miller Cardiology · New York, NY	11	28

Refers patients to

Outbound — where patients go next

No outbound pairs above the suppression threshold.

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history